Harley Goldberg1, William Firtch2, Mark Tyburski3, Alice Pressman4, Lynn Ackerson5, Luisa Hamilton5, Wayne Smith6, Ryan Carver3, Annu Maratukulam2, Lawrence A Won6, Eugene Carragee7, Andrew L Avins8. 1. Kaiser Permanente Northern California Spine Care Program, San Jose2Division of Research, Kaiser Permanente Northern California, Oakland. 2. Kaiser Permanente Northern California Spine Care Program, Redwood City. 3. Kaiser Permanente Northern California Spine Care Program, Roseville. 4. Division of Research, Kaiser Permanente Northern California, Oakland5Sutter Health Research, Development, and Dissemination, Walnut Creek, California. 5. Division of Research, Kaiser Permanente Northern California, Oakland. 6. Kaiser Permanente Northern California Spine Care Program, San Jose. 7. Orthopedic Spine Surgery Division, Department of Orthopedics, Stanford University, Palo Alto, California. 8. Division of Research, Kaiser Permanente Northern California, Oakland7Department of Medicine, University of California, San Francisco8Department of Epidemiology and Biostatistics, University of California, San Francisco.
Abstract
IMPORTANCE: Oral steroids are commonly used to treat acute sciatica due to a herniated disk but have not been evaluated in an appropriately powered clinical trial. OBJECTIVE: To determine if oral prednisone is more effective than placebo in improving function and pain among patients with acute sciatica. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, placebo-controlled clinical trial conducted from 2008 to 2013 in a large integrated health care delivery system in Northern California. Adults (n=269) with radicular pain for 3 months or less, an Oswestry Disability Index (ODI) score of 30 or higher (range, 0-100; higher scores indicate greater dysfunction), and a herniated disk confirmed by magnetic resonance imaging were eligible. INTERVENTIONS: Participants were randomly assigned in a 2:1 ratio to receive a tapering 15-day course of oral prednisone (5 days each of 60 mg, 40 mg, and 20 mg; total cumulative dose = 600 mg; n = 181) or matching placebo (n = 88). MAIN OUTCOMES AND MEASURES: The primary outcome was ODI change at 3 weeks; secondary outcomes were ODI change at 1 year, change in lower extremity pain (measured on a 0-10 scale; higher scores indicate more pain), spine surgery, and Short Form 36 Health Survey (SF-36) Physical Component Summary (PCS) and Mental Component Summary (MCS) scores (0-100 scale; higher scores better). RESULTS: Observed baseline and 3-week mean ODI scores were 51.2 and 32.2 for the prednisone group and 51.1 and 37.5 for the placebo group, respectively. The prednisone-treated group showed an adjusted mean 6.4-point (95% CI, 1.9-10.9; P = .006) greater improvement in ODI scores at 3 weeks than the placebo group and a mean 7.4-point (95% CI, 2.2-12.5; P = .005) greater improvement at 52 weeks. Compared with the placebo group, the prednisone group showed an adjusted mean 0.3-point (95% CI, -0.4 to 1.0; P = .34) greater reduction in pain at 3 weeks and a mean 0.6-point (95% CI, -0.2 to 1.3; P = .15) greater reduction at 52 weeks. The prednisone group showed an adjusted mean 3.3-point (95% CI, 1.3-5.2; P = .001) greater improvement in the SF-36 PCS score at 3 weeks, no difference in the SF-36 PCS score at 52 weeks (mean, 2.5; 95% CI, -0.3 to 5.4; P = .08), no change in the SF-36 MCS score at 3 weeks (mean, 2.2; 95% CI, -0.4 to 4.8; P = .10), and an adjusted 3.6-point (95% CI, 0.6-6.7; P = .02) greater improvement in the SF-36 MCS score at 52 weeks. There were no differences in surgery rates at 52-week follow-up. Having 1 or more adverse events at 3-week follow-up was more common in the prednisone group than in the placebo group (49.2% vs 23.9%; P < .001). CONCLUSIONS AND RELEVANCE: Among patients with acute radiculopathy due to a herniated lumbar disk, a short course of oral steroids, compared with placebo, resulted in modestly improved function and no improvement in pain. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00668434.
RCT Entities:
IMPORTANCE: Oral steroids are commonly used to treat acute sciatica due to a herniated disk but have not been evaluated in an appropriately powered clinical trial. OBJECTIVE: To determine if oral prednisone is more effective than placebo in improving function and pain among patients with acute sciatica. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, placebo-controlled clinical trial conducted from 2008 to 2013 in a large integrated health care delivery system in Northern California. Adults (n=269) with radicular pain for 3 months or less, an Oswestry Disability Index (ODI) score of 30 or higher (range, 0-100; higher scores indicate greater dysfunction), and a herniated disk confirmed by magnetic resonance imaging were eligible. INTERVENTIONS:Participants were randomly assigned in a 2:1 ratio to receive a tapering 15-day course of oral prednisone (5 days each of 60 mg, 40 mg, and 20 mg; total cumulative dose = 600 mg; n = 181) or matching placebo (n = 88). MAIN OUTCOMES AND MEASURES: The primary outcome was ODI change at 3 weeks; secondary outcomes were ODI change at 1 year, change in lower extremity pain (measured on a 0-10 scale; higher scores indicate more pain), spine surgery, and Short Form 36 Health Survey (SF-36) Physical Component Summary (PCS) and Mental Component Summary (MCS) scores (0-100 scale; higher scores better). RESULTS: Observed baseline and 3-week mean ODI scores were 51.2 and 32.2 for the prednisone group and 51.1 and 37.5 for the placebo group, respectively. The prednisone-treated group showed an adjusted mean 6.4-point (95% CI, 1.9-10.9; P = .006) greater improvement in ODI scores at 3 weeks than the placebo group and a mean 7.4-point (95% CI, 2.2-12.5; P = .005) greater improvement at 52 weeks. Compared with the placebo group, the prednisone group showed an adjusted mean 0.3-point (95% CI, -0.4 to 1.0; P = .34) greater reduction in pain at 3 weeks and a mean 0.6-point (95% CI, -0.2 to 1.3; P = .15) greater reduction at 52 weeks. The prednisone group showed an adjusted mean 3.3-point (95% CI, 1.3-5.2; P = .001) greater improvement in the SF-36 PCS score at 3 weeks, no difference in the SF-36 PCS score at 52 weeks (mean, 2.5; 95% CI, -0.3 to 5.4; P = .08), no change in the SF-36 MCS score at 3 weeks (mean, 2.2; 95% CI, -0.4 to 4.8; P = .10), and an adjusted 3.6-point (95% CI, 0.6-6.7; P = .02) greater improvement in the SF-36 MCS score at 52 weeks. There were no differences in surgery rates at 52-week follow-up. Having 1 or more adverse events at 3-week follow-up was more common in the prednisone group than in the placebo group (49.2% vs 23.9%; P < .001). CONCLUSIONS AND RELEVANCE: Among patients with acute radiculopathy due to a herniated lumbar disk, a short course of oral steroids, compared with placebo, resulted in modestly improved function and no improvement in pain. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00668434.
Authors: James N Weinstein; Tor D Tosteson; Jon D Lurie; Anna N A Tosteson; Brett Hanscom; Jonathan S Skinner; William A Abdu; Alan S Hilibrand; Scott D Boden; Richard A Deyo Journal: JAMA Date: 2006-11-22 Impact factor: 56.272
Authors: Benjamin W Friedman; David Esses; Clemencia Solorzano; Hong K Choi; Michael Cole; Michelle Davitt; Polly E Bijur; E J Gallagher Journal: Spine (Phila Pa 1976) Date: 2008-08-15 Impact factor: 3.468
Authors: Rafael Zambelli Pinto; Chris G Maher; Manuela L Ferreira; Mark Hancock; Vinicius C Oliveira; Andrew J McLachlan; Bart Koes; Paulo H Ferreira Journal: Ann Intern Med Date: 2012-12-18 Impact factor: 25.391
Authors: Roger Chou; Rafael Zambelli Pinto; Rongwei Fu; Robert A Lowe; Nicholas Henschke; James H McAuley; Tracy Dana Journal: Cochrane Database Syst Rev Date: 2022-10-21
Authors: William C Becker; Matthew J Bair; Michael Picchioni; Joanna L Starrels; Joseph W Frank Journal: Pain Med Date: 2018-01-01 Impact factor: 3.750
Authors: Sanjog S Pangarkar; Daniel G Kang; Friedhelm Sandbrink; Adam Bevevino; Kirsten Tillisch; Lisa Konitzer; James Sall Journal: J Gen Intern Med Date: 2019-09-16 Impact factor: 5.128
Authors: Chang Liu; Christina Abdel Shaheed; Andrew J McLachlan; Jane Latimer; Qiang Li; Rachelle Buchbinder; Richard O Day; Christopher G Maher; Bethan Richards; Juliana S Oliveira; Chung-Wei Christine Lin Journal: BMJ Open Date: 2020-06-23 Impact factor: 2.692
Authors: Monica Rho; Alejandra Camacho-Soto; Abby Cheng; Mark Havran; Natalia E Morone; Eric Rodriguez; Joseph Shega; Debra K Weiner Journal: Pain Med Date: 2016-07-01 Impact factor: 3.750